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This systematic review describes what “the cutting edge vaccines for Aeromonas hydrophila are”. The focus is on types of high
tech biotechnological based vaccines, target gene or antigen in developing these vaccines, and challenge model fish species used
in vaccines efficacy testing. Vaccines delivery methods, immune response, and their efficacy, adjuvant or carrier systems used, and
the overall experimental setup or design of the vaccines under investigation are also described. The search for the original papers
published between 2009 and 2018was conducted in June of 2018, using the PubMed andGoogle scholar electronic database. Twenty-
three (23/4386) studies were included in the final assembly using PRISMA guidelines (Protocol not registered). Recombinant
protein vaccines were the highly experimented type of the modern biotechnological based vaccines identified in the selected
studies (16/23; 70%). Outer membrane proteins (OMPs) of different 𝛽-barrels were shown to be a potential antigenic entity for
A. hydrophila vaccines (57%). Intraperitoneal route with conventional carries or adjuvants was the highly applied delivery system
while very few studies used herbal based vaccine adjuvants and nanomaterial as a vaccine carrier. Variation was observed in
terms of protection levels in the selected studies. The experimental designs partly contributed to the observed variation.Therefore,
recombinant vaccines that use new carrier system technologies and delivered through oral route in feeds would have been of great
value for use in the prevention and control of A. hydrophila infections in fish. Despite the usefulness as academic tools to identify
what is important in pathogenicity of the etiological agent to the host fish, these vaccines are only economically viable in very
high-value animals. Therefore, if vaccination is a good option for A. hydrophila group, then simple autogenous vaccines based on
accurate typing and evidence-based definition of the epidemiological unit for their use would be the most viable approach in terms
of both efficacy and economic feasibility especially in low and middle-income countries (LMIC).
1. Introduction
Aquaculture has been stipulated to play a prodigious role
in food security after fisheries. It serves as a source of
income at the household level as well as at the national
level in developed and developing countries [1]. Due to great
demand for fish protein, the aquaculture sector attracted
great attention and it is a fast-growing agricultural sector [2].
Tomaximize yield, the culture system has become in practice
more intensively and hence among others, fish diseases have
started to become a disaster especially in countries where
aquaculture is operational [3]. Bacterial diseases are the most
leading causes of fish mortality in aquaculture. Despite the
known contributions of other species of the genusAeromonas
in causing diseases in fish, A. hydrophila is the main cause of
disease outbreaks in freshwater farmed fish contributing to
food insecurity and economic loss worldwide [4–6].The bac-
terium causes various diseases in fish named as haemorrhagic
septicaemia, dropsy, epizootic ulcerative syndrome, haemor-
rhagic enteritis, and red body disease [7, 8]. Aeromonads dis-
eases in fish farms are accelerated by several factors including
variations in physical-chemical parameters of pond water.
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Despite the fact that vaccination represents the most
effective strategy to prevent diseases in the aquaculture
industry [30], commercial vaccines for A. hydrophila in fish
have been a challenge [6]. This gram-negative rod-shaped
bacterium of the familyAeromonadaceae causes several signs
of ill health including tail and skin rot and fatal haemor-
rhagic septicaemias in several fish species [31]. Owing to
its nature of being ubiquitous of the aquatic environment,
this bacterium has become a thought-provoking pathogen of
fish which requires maximum pond management practices
and biosecurity measures to control it [14]. Although the
application of antibiotics is not healthy for fish consumers,
still its effectiveness is questionable because of the delay of
disease diagnosis and increase in antibiotic resistance, which
has been shown by the bacterium worldwide [32].
One of the problems that limit the development of
commercialA. hydrophila vaccines is strain diversity [33] and
failure of the vaccine to confer protection to heterologous
strains [34]. However, an effort has been made to develop
vaccines in different regions worldwide, initially focusing on
inactivated products and live attenuated organisms. Follow-
ing advancement made in molecular biology, biotechnology,
vaccine immunology, and reverse vaccinology, new high
tech vaccines are being developed and experimentally tested
against A. hydrophila in different fish species. Therefore, this
systematic review describes what the current knowledge in
A. hydrophila vaccines development is. The focus is on types
of high tech biotechnological based vaccines, target gene or
antigen in developing these vaccines, and challenge model
fish species used in vaccines efficacy testing. Vaccines delivery
methods, immune response, and their efficacy, adjuvant or
carrier systems used, and the overall experimental setup or
design of the vaccines under investigation are also described.
The rationale for reviewing these vaccines to this specific
pathogen was that, in past years, vaccination has significantly
contributed tominimizing the disease burden in the aquacul-
ture system using conventional vaccines. However, the use of
modern biotechnological vaccines has the potential to fill the
gap between vaccine efficiency and increased demand. To the
best of our knowledge, this systematic review is of its own
kind that looked at these studies onmodern biotechnological
vaccines against A. hydrophila as a whole.
2. Methodology
2.1. Searching Strategy and Selection Criteria. The following
search words, “DNA” or “Recombinant” or “Subunit” and
“Vaccines “and A. hydrophila and in fish, were used in
combination with Boolean operator search as described by
Boell and Cecez-Kecmanovic [35, 36] to identify articles to
be included in this systematic review. The search for the
papers was conducted in June of 2018, using the PubMed
and Google scholar electronic database. Hand searching for
a bibliography of included studies to identify any other
potential articles was also done. The following criteria were
used for including a source in the study: publications had to
be in English; the publication date had to be between 2009
and 2018; the published articles had to be an original article;
experiments on the immunological responses and efficacy
had to be done in fish and the delivery methods information
of the vaccine under test had to be available; the studies had
to focus on fish vaccines against A. hydrophila leading to the
rejection of all or most fish vaccines related to other bacterial
species.This review iswritten following the PRISMAmethod;
however, this protocol was not registered with PRISMA.
2.2. Data and InformationCollection Process. All publications
which met the inclusion criteria were entered in Mandalay
reference manager and publications were ordered by primary
authors. Information was extracted from each included study
on type of modern biotechnological based A. hydrophila
vaccines in fish (e.g., plasmid DNA vaccine, recombinant
protein vaccine), target gene or antigen in developing A.
hydrophila vaccine in fish, working mechanism in relation
to immune responses and protection, challenge model fish
species used in vaccine efficacy testing, deliverymethods, and
adjuvants and/or carrier system employed.
3. Results and Discussion
3.1. Description of Literature Search Outcome. In literature
searching, 4386 articles were identified from both PubMed
and Google scholar, of which 4310 were irrelevant and
excluded just after screening the manuscript titles while 73
articles (Figure 1) seemed to be relevant to the study in
question. A further detailed assessment of titles and abstract
revealed 21 articles (n=21) that were not forA. hydrophila, not
either DNA based or recombinant vaccine but just molecular
characterization of immunogenic genes and therefore were
excluded from this review. On the other hand, some articles
were not included in the analysis as they missed inclusion
criteria or other overbearing reasons such as duplicate articles
(n = 17); articles lacking full text (n = 2); articles in which the
vaccine test model was not fish (n = 9); and 1 article in which
the text was in Chinese language. Of the articles in which the
test model was not fish, 5 used mice as a test model but the
vaccine is anticipated to protect fish and the test model of 4
articles were mice but the vaccine aimed to protect humans.
The most important findings and information revealed
and extracted from eligible articles (n = 23) used in this
systematic review were types of modern biotechnological
vaccines against A. hydrophila in fish; target gene or antigen
used in developing A. hydrophila vaccine in fish; working
mechanism in relation to immune responses and efficacy
evaluation; challenge model fish species involved in vaccine
efficacy testing (Table 1), delivery methods used and adju-
vant/ carrier system employed. Most of the selected articles
from this review emanated from the findings obtained from
China (12/23; 52%) followed by India (5/23; 22%) (Table 2).
The criteria used to exclude some studies from the review
have been shown in Figure 1.
3.2. Types of Modern Biotechnological Vaccines against A.
hydrophila in Fish. It is evident that whole organism vaccines
(killed and attenuated vaccines) showed better advantages
than other types of vaccines. Attenuated vaccines, for exam-
ple, have great potential in aquaculture in the sense that
they provide a simulation model of infection and the vaccine
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Figure 1: A flow diagram showing inclusion and exclusion criteria of selected studies for this systematic review.
strain could spread to a nonvaccinated fish population over
a prolonged period of time. Furthermore, live attenuated
vaccines have the advantage that they stimulate humoral
and cellular immunity significantly in fish. But the matter
of fact is that not all these vaccines completely prevent
disease and in addition have safety concerns [37], a time-
consuming process, which delays the timely development
of vaccines against emerging and reemerging pathogens of
fish. Therefore, novel approaches through advances made in
genetics, biotechnology, immunology, andmolecular biology
[38–40] were needed for discovering newer types of effective
vaccines in the aquaculture field.
From the reviewed articles, advances in molecular biol-
ogy, biotechnology, and reverse vaccinology have enabled
the development of different types of A. hydrophila vaccines
which have recently been experimentally tested in fish. They
include subunit vaccines, plasmid DNA vaccines, the recom-
binant live vector vaccines, and recombinant protein vaccines
of which some approaches towards their developments have
been shown in Figure 2. Three articles (n= 23) worked on
DNA vaccines and only one article tested the recombinant
live vectored vaccine (n=23) (Table 1).
DNA vaccinations against a wide range of pathogens have
been investigated in various fish species especially against
viral diseases but limited in bacterial diseases. Pridgeon and
Klesius [28, 29] reported a high protective vaccine efficacy
of 100% for their DNA vaccine delivered through intraperi-
toneal injection in channel catfish 2 days post injection
while Liu et al. [27] on the other hand observed a relatively
lower protective vaccine efficacy of about 68.9% for the DNA
vaccine delivered through intramuscular injection. In spite
of having several advantages such as conferring immediate,
safe, and durable protection against several viral diseases such
as infectious hematopoietic necrosis virus (IHNV) [5, 41] in
farmed fish, this type of vaccine seemed to be less adopted
in bacterial diseases and especially in controlling diseases
caused by A. hydrophila in farmed fish. Among others,
one reason given by researchers was bacteria having genes
involved in the production of carbohydrates and highly gly-
cosylated proteins of which transcription and production of
plasmid DNA encoding these genes are not feasible but only
possible for nonglycosylated proteins [42]. Thus DNA vacci-
nation could not probably be a good alternative substitute for
the more traditional polysaccharide containing vaccines in
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Table 1: Summary of vaccines and the delivery systems used in the selected studies.
Type of vaccine Adjuvant/vaccinecarrier system Country Reference
Subunit vaccine - China [9]
Subunit vaccine Montanide andaluminium hydroxide Turkey [10]
Subunit vaccine Asparagus racemosusextracts India [11]














vaccine Freund’s adjuvant Malaysia [14]
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nanotubes (SWCNTs) China [17]
Recombinant protein
vaccine - China [18]
Recombinant protein
vaccine - India [19]
Recombinant protein
vaccine ISA 763 adjuvant China [20]
Recombinant protein
vaccine Freund's adjuvant China [21]
Recombinant protein




nanotubes (SWCNTs) China [23]
Recombinant protein
vaccine Freund's adjuvant China [24]
Recombinant protein
vaccine ISA 763 adjuvant China [25]
Recombinant protein
vaccine PLGA Nanoparticle India [26]
DNA vaccine single-walled carbonnanotubes (SWCNTs) China [27]
DNA vaccine QCDCR adjuvant USA [28]
DNA vaccine QCDCR adjuvant USA [29]
triggering immune responses against microbes that have an
outer membrane made of, for example, lipopolysaccharides
[43]. The reported possibilities of developing myositis upon
intramuscular injection of plasmidDNA (pDNA) are another
challenge limiting its use against bacterial infection in fish.
In this review, it has been observed that only one and
indeed very few studies focused on experimenting on recom-
binant live vectored vaccines against A. hydrophila in fish.
The study utilised nonpathogenic recombinant Lactococcus
lactis to carry an aerolysin gene from A. hydrophila. Live
vaccines, be it attenuated pathogens or microbial vectors
carrying epitopes of the pathogen, always promote a potent
immune response as it mimics natural infections and has
intrinsic adjuvant properties than nonreplicating products
[37]. However, as it has been explained by Vaughan et al. [44]
that immunization with such vaccines unavoidably infers
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Table 2: Summary of experimented A. hydrophila fish vaccines in terms of antigenic entity used, fish models, route of administration, and
reported efficacy.
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Figure 2: Schematic representation of types of modern biotechnological based A. hydrophila vaccines development employed in the selected
studies.
the release of recombinant organisms into the surrounding
environment thus based on European Union (EU) and other
guidelines, such organisms are pigeonholed as genetically
modified organisms (GMO), limiting their potential utilisa-
tion and this could be the reason of very few publications of
this kind of vaccines experimented against A. hydrophila in
fish.
Recombinant protein vaccines seem to take a wide cov-
erage in controlling most of the bacterial diseases in fish.
This is depicted by a number of studies experimenting on
recombinant protein vaccines against A. hydrophila diseases
in fish, as 70% of the articles (16/23) analysed in this system-
atic review reported experimental findings of recombinant
protein vaccines against A. hydrophila. These vaccines are
prepared by taking only the immunogenic regions of a
pathogen and insert it in an expression host that expresses the
protein on a large scale and then later the protein is purified
as a vaccine [45]. Initially, the development of this type
vaccine was a bit tedious especially in the characterization of
an immunogenic component of the pathogen, but following
advancement in reverse vaccinology; vaccine development
can take one to two years. In addition to quick development,
vaccine safety is guaranteed upon the usage of safe and
appropriate vaccine delivery systems and adjuvants. It is
because of these reasons and many other vaccinologists have
put the effort into experimenting on this type of vaccine
against A. hydrophila in different fish species.
As advocated byDalmo [46], we also agree that all of these
vaccine development strategies have merits and demerits,
and their use will depend on nature of the mechanisms of
infection of the particular pathogen and respective immune
response required for protection.
3.3. Target Gene or Antigen in Developing A. hydrophila
Vaccines in Fish. It has been observed that 57% of the
experimental vaccines for A. hydrophila in the selected
studies targeted the outer membrane proteins of different 𝛽-
barrels as the potential antigenic entity while others used
lipopolysaccharide (LPS), aerolysin genes, N-acyl homoser-
ine 1 lactonase, glycoprotein, recombinant S-layer protein,
G-protein coupled receptor 18 (GPR18), and apolipoprotein
(Table 2).
Outer membrane proteins (OMPs) serve as an interface
between the host and the pathogen. The use of OMPs in
several studies for A. hydrophila recombinant and subunit
vaccines design to develop vaccine candidates because of
their association with pathogenesis, adherence, and the inva-
sion of the pathogen to the host fish is well recognised [18].
The OMPs serve as an interface between the pathogen and
the immune cells. Therefore, the use of OMPs in most of the
experimental vaccines in the selected studies may have been
driven by the reported protection success of few OMPs from
various bacterial species in fish [6].
Although there are other antigenic targets that have been
proved to confer immunity in fish against A. hydrophila, it
is our filling that the increasingly use of recombinant OMPs
as vaccines candidates for A. hydrophila in fish came after
realisation of conserved nature of antigenic determinants that
induce specific immune system in the host fish, providing
solution against the existing antigenic strains diversity hurdle
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in development of effective commercial vaccines against the
bacterium (Lutwyche et al. 1995) [6]. Therefore in addition
to the reported attributes of inducing specific antibodies,
inhibiting bacterial colonization, and inducing cell-mediated
immunity, its conserved nature provides cross-protection
against several bacterial strains and species in fish.
Although most of the OMPs of different 𝛽-barrels have
been shown to be potential candidate vaccines against
A. hydrophila, we apparently assume that the synergistic
immune response would have been reached when these
were combined and therefore further research should be
directed on testing the combination of these OMPs barrels
in recombinant protein vaccine formulation.
3.4. Model Fish Species Used in Vaccine Efficacy Testing. The
use of grass carp as a fishmodel in testing the experimentedA.
hydrophila vaccines has been observed in four studies (4/23;
17%; Table 2). Similarly, four studies (4/23; 17%) reported
having used Channel Catfish as a vaccine testing model.
Rohu has been used in three studies (3/23; 13%) while only
one study (1/23; 4%) tested the vaccine efficacy on tilapia.
Twelve studies (12/23; 52%) used different fish model species.
Fish is a heterogeneous cluster of organisms that include
the agnathans (lampreys and myxines), condryctians (sharks
and rays), and teleosteans (bony fish) [47]. Despite the fact
that vaccines in aquaculture are specific to fish species, the
variability observed in experimental challenge fish species
used in vaccine trials may have been also backed by the
most common farmed fish in respective location or region
the study has been carried out. Most of the studies included
in this review originated from Asia (17/23, 74%) where the
common carp and grass carp are cultured in many countries
in Asia and Europe [48]. As Mitchell [49] put it, that limited
number of vaccines for tilapia is available today making this
market segment of tilapia vaccines relatively novel.
3.5. Vaccines Delivery Methods. Vaccine administration in
fish is done through different routes such as oral administra-
tion, intramuscularly, intraperitoneal injection, and through
immersion. In the selected studies, the administration of
experimentedA. hydrophila vaccines by intraperitoneal injec-
tion has been reported by eighteen studies (18/23; 78%;
Table 1) while only one study used bath immersion (1/24;
4%) to vaccinate the model fish. While efforts are made by
researchers to improve vaccine carriers in a way that can
accommodate mass vaccination of fish, vaccine delivery for
most of the bacterial fish vaccines through intraperitoneal
injection and for DNA vaccines through intramuscular injec-
tion has currently been common in fish.
The increased number of studies in using intraperitoneal
injection to deliver the vaccines has been accelerated on
the truth that the method gives high protection compared
to other delivery systems (Table 2). As it was pointed out
by Plant and LaPatra [50], the challenges with this delivery
method are that they pose stress to fish, labour intensive
and therefore costly and it is suitable for large size fish.
Contrary to the injection method, dip and bath immersion
is applied to vaccinate fish of all sizes using a different
concentration of vaccines. However, this method is pointed
to have low vaccine protection of which scientists proved to
be caused by poor vaccine antigen uptake through skin and
gills. It is just in 2002 where Nakanishi et al. [51] reported
high protection of a vaccine against Streptococcus iniae in
rainbow trout (Oncorhynchusmykiss) using a novel approach,
a skin puncture followed by immersion delivery system.
Nevertheless, we concede with animal welfare activist and
other scientists that the method increases stress to fish more
than that induced during injection method.
Oral administration is another method of vaccine deliv-
ery useful for mass vaccination of fish, and it is normally
employed through feeds. In this study, only 3 articles assessed
their vaccines protection status using oral administration.
Anuradha et al. [14] reported live recombinant vaccine
protection of 70 to 100% using Fraund’s adjuvant as vaccine
carrier while Dubey et al. [26] on the other hand assessed
the recombinant protein vaccine using nanoparticles, that is,
PGLA reporting protection of 37 to 80% through the same
route. Furthermore, findings from other various scientists
have revealed that naked antigens are prone to degradation
in the foregut of the fish due to the acidic environment
before reaching the hindgut where adherence and immune
responses are elicited [52]. The inactivated and unencapsu-
lated vaccines seem to be highly affected by the situation
compared to live vaccines. It is also well documented that
oral vaccine administration does not give reliable protection
because of inconsistency in vaccine uptake by fish. We,
therefore, emphasize working on targeted delivery strategies
which are being used for oral vaccine development in humans
and other animal species to be used extensively in vaccines
against A. hydrophila in fish.
3.6. Adjuvant/Vaccine Carrier System. An immunologic
adjuvant is applied to accelerate, prolong, or enhance antigen-
specific immune response when combined with specific
antigens [53]. Search for safer and potent vaccine adjuvants
and carrier system has resulted in the formulation of antigen
into different carrier systems from those of historical solution
form to modern adjuvants and carrier system in particulate
form. These adjuvants and carrier systems range from those
of chemical-based to biological ones.
A number of scientists have said that chemical adjuvants
have been historically used to enhance the efficacy of vaccines
in humans, animals, and fish [54]. This is in agreement
with what has been revealed in the selected studies, where
Montanide adjuvants, Freund’s adjuvants, and other conven-
tional chemical adjuvants (4/23; 17% each) are the leading
carrier systems used in an experimental vaccine against A.
hydrophila in fish. Despite the reported efficiency, we concede
to those who say that the conventional chemical adjuvants
and vaccine carriers also produce adverse effects to the host
such as chronic peritonitis, adhesions, and granulomas in
extreme conditions [6, 55, 56].
Due to that, the search for better carrier systems that
provide improved vaccine efficacy especially in new gen-
eration vaccines such as subunit, DNA, and recombinant
protein vaccineswas instigated.Theuse of biological adjuvant
such as molecular adjuvants, i.e., plasmid-encoded cytokine
adjuvants in DNA vaccines [57], herbal based adjuvants, i.e.,
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Asparagus racemosus extracts [11], nanotubes, and nanopar-
ticles have gained special attention in human and animal
vaccines [26]. However, as it has been observed in this review
of modern biotechnological based A. hydrophila vaccines
(Table 1), the application of these new carrier systems is
nearly inattentive in fish. Only two studies used the biological
based adjuvants, the A. racemosus extracts (Thangaviji et al.
2012) andmodified herbal adjuvant [6]. Four studies reported
the use of nanomaterials as vaccine carrier system for A.
hydrophila vaccines, which includes single-walled carbon
nanotubes (SWCNTs) (3/4) and poly lactic-co-glycolic acid
(PLGA) nanoparticle (1/4) (Table 1).
Microencapsulation of vaccines in polymers such as
chitosan, MicroMatrix, alginates, liposome, and poly
D,L-lactic-co-glycolic acid (PLGA) are the current novel
approaches towards improving oral vaccines incorporated
in the feed [52]. The application of biodegradable PLGA
nanoparticles, for example, has attracted a lot of interest as
an antigen carrier system for oral vaccines because of their
ability to enhance antigen uptake and ability to allow the slow
release of antigens in vivo [26] and therefore we advocate
research on nanomaterial carrier systems for oral vaccines
against A. hydrophila in fish as the use of injectable vaccines
in mass vaccination of fish becomes complicated.
3.7. Working Mechanism in Relation to Immune Responses
and Vaccine Efficacy. Vaccines work by inducing either
humoral immunity or both humoral and cellular immunity.
In the selected study, only four studies (4/23; 17%) reported
having assessed the humoral and adaptive cellular immune
response of their vaccines while the majority reported innate
and antibody-mediated immunity only without the adaptive
cellular immunity. This is in agreement with what was
observed by Munang’andu and Evensen [58] that very few
studies in fish immunology showed protection capacity of
cell-mediated immunity. Although it is well known that the
immune response in fish resembles that of mammals with
some specific differences between them [59], assessment of
the immune responses in fish is not a straightforward activity.
The measurement of humoral immunity can be possible but
on the other hand, cell-mediated immunity cannot be easily
assessed [7]. This perhaps could be the reason why most of
the studies included in this review failed to assess the adaptive
cell-mediated immunity.
In line with that, the challenges in designing these
new kinds of vaccine strategies to elicit the appropriate
cellular immunity [45, 58] and the extracellular nature of
the bacterium could be another reason of assessing the
humoral immunity rather than cellular immunity. Correlate
of protection (CoP) has been established for some licensed
human and animal bacterial vaccines [46]. This could be
an additional reason that drove researchers in the selected
studies to opt to assess the antibody responses as correlate
of protection without cell-mediated immunity; however a
study conducted by Abdelhamed et al. [7] on recombinant A.
hydrophila vaccine in fish revealed that antibodies responses
did not correlate with the protection level while the relative
percent survival (RPS) showed fish to be protected following
challenge. Abdelhamed et al. [7] therefore explained this sce-
nario by acknowledging that antibodies do not account for all
of the protection and the predominance of cellular immunity
over the antibodies responses cannot be undervalued.
Most of the selected studies assessed vaccine efficacy in
terms of RPS, of which four studies did so without assess-
ing vaccine immunogenicity. Nonetheless understanding the
immunologicalmechanism of the vaccine under study is very
important. Furthermore irrespective of the reported promis-
ing vaccine efficacies (in terms RPS) abridged in Table 1, it
is hard to draw general conclusions because of differences in
experimental design observed in the selected studies (Table 3)
such as the dose, vaccine type, challenge fish model species,
interval between vaccination and challenge (Table 3), route of
administration (Table 2), and vaccine adjuvant effects. Most
of the selected studies conducted an experimental vaccine
challenges 30 days postvaccinationwhile only 1 conducted for
120 days postvaccination.
As Johansen et al. [60] put it, we also insist that common
experimental design and guidelines for specific fish species
in addition to other general guidelines such as that devel-
oped by European Medicine Agency (EMA) [61] should be
established. This will assist researchers to have a common
understanding of protection trials of their newly developed
vaccines in fish.
Therefore it is here emphasized in agreement with
Mweemba and Evensen [62] that consensus should be
reached on a correlate of protection based on challenge mod-
els, measures of efficacy, and immunological mechanisms of
vaccine protection.
4. Conclusion
Recombinant vaccines that use new carrier system technolo-
gies and are delivered through oral route in feeds would
have been of great value for use in the prevention and
control of A. hydrophila infections in fish as it could support
mass vaccination in a similar way it does in other bacterial
diseases in fish. However, recombinant vaccines are really
useful academic tools in identifying what is important in
pathogenicity of the etiological agent to the host fish but
are only economically viable in very high-value animals.
Therefore, if it is believed that vaccination is a good option
for A. hydrophila group, then simple autogenous vaccines
based on accurate typing, diagnostics, and evidence-based
definition of the epidemiological unit for their use would
be the most viable approach in terms of both efficacy and
economic feasibility especially in low and middle-income
countries (LMIC).
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Table 3: Synopsis of experimental setup of vaccine testing in the selected studies.





Gong et al. 2015 1920 720 540 28
Dash et al. 2014 870 90 180 56 and 140
Cao et al. 2012 720 - - -
Abdelhamed et al. 2016 700 70 - 21
Liu et al. 2016 640 240 240 21
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Pridgeon & Klesius, 2013
[29] 420 - 420
2, 4, 14, 24, 28 and
48
Pridgeon & Klesius, 2013
[28] 420 - 420
2, 4, 14, 24, 30 and
48
Sun et al. 2010 400 - 80 35
Feng et al. 2017 360 72 90 28
Liu et al. 2015 300 - - -
Wang et al. 2013 300 300 90 45
Wang et al. 2015 300 144 90 45
Maiti et al. 2012 270 54 270 24
Thangaviji et al. 2012 240 - 180 30 and 60
Poobalane et al. 2010 240 - 240 35
Songlin et al. 2015 180 60 48 28
Wang et al. 2017 180 - 180 7 and 14
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Çiftci et al. 2016 100 100 100 21
Khushiramani et al. 2012 100 100 100 10
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